This article was originally published on TipRanks.com ImmunoGen Inc.
Shares of ImmunoGen spiked 14.2% on Monday after the biotechnology company said that the U.
On Wall Street, some things never change. Public health crisis or not, the fact of the matter remains that healthcare stocks are the …
ImmunoGen, Inc. (NASDAQ:IMGN) shares are rallying today thanks to news of a collaboration agreement with Jazz Pharmaceuticals (NASDAQ:JAZZ) for the development and commercialization …
ImmunoGen, Inc. (NASDAQ:IMGN), a biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology, today reported financial results for the three-month …
After ImmunoGen, Inc. (NASDAQ:IMGN) announced that Takeda, a Japanese pharmaceutical company, will license their new cancer therapies that use novel antibody drug conjugate (ADC) technology, Oppenheimer …
In a research report sent to investors, Cantor analyst Mara Goldstein reiterated a Hold rating on ImmunoGen (NASDAQ:IMGN) with a $9.00 price target, following …
In a research report published Monday, Cantor analyst Mara Goldstein maintained a Hold rating on ImmunoGen (NASDAQ:IMGN) and reduced her price target to $9 (from $14), …
In a research note published Monday, Oppenheimer analyst Christopher Marai assigned a Perform rating on ImmunoGen (NASDAQ:IMGN), No price target was provided. Marai commented: “ImmunoGen reported …
In a research report issued today, William Blair analyst John Sonnier assigned an Outperform rating on ImmunoGen (NASDAQ:IMGN). No price target was provided.